(Q39184115)

English

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models

scientific article published on 7 March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models (English)

1 reference

Europe PubMed Central

9 September 2017

endometrial cancer

1 reference

based on heuristic

inferred from title

David P. Miller

4

object named as

David Miller

1 reference

Europe PubMed Central

9 September 2017

author name string

Joseph M Gozgit

1

1 reference

Europe PubMed Central

9 September 2017

Rachel M Squillace

2

1 reference

Europe PubMed Central

9 September 2017

Matthew J Wongchenko

3

1 reference

Europe PubMed Central

9 September 2017

Scott Wardwell

5

1 reference

Europe PubMed Central

9 September 2017

Qurish Mohemmad

6

1 reference

Europe PubMed Central

9 September 2017

Narayana I Narasimhan

7

1 reference

Europe PubMed Central

9 September 2017

Frank Wang

8

1 reference

Europe PubMed Central

9 September 2017

Tim Clackson

9

1 reference

Europe PubMed Central

9 September 2017

Victor M Rivera

10

1 reference

Europe PubMed Central

9 September 2017

publication date

7 March 2013

1 reference

Europe PubMed Central

9 September 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

9 September 2017

71

1 reference

Europe PubMed Central

9 September 2017

5

1 reference

Europe PubMed Central

9 September 2017

1315-1323

1 reference

Europe PubMed Central

9 September 2017

https://scigraph.springernature.com/pub.10.1007/s00280-013-2131-z

0 references

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Drug-sensitive FGFR2 mutations in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Molecular and pathologic aspects of endometrial carcinogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase includ

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Ponatinib in refractory Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Targeting the mTOR pathway using deforolimus in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Resistance to chemotherapy and hormone therapy in endometrial cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

FGFR2 as a molecular target in endometrial cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Targeting the PI3K/AKT pathway for the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2131-Z

21 January 2018

Identifiers

10.1007/S00280-013-2131-Z

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39184115&oldid=1894347976"